ON 146040 is a potent PI3Kα and PI3Kδ (IC₅₀≈14 and 20 nM, respectively) inhibitor. ON 146040 also inhibits Abl1 (IC₅₀<150 nM).

In biochemical testing, ON 146040 inhibits PI3Kα/ PI3Kδ isoforms (IC₅₀≈14 and 20 nM, respectively) without having a major effect on PI3Kβ/ PI3Kγ isoforms (IC₅₀≈3 and 1 μM, respectively). ON 146040 is also found to inhibit Abl1 and several mutant versions of this kinase (IC₅₀<150 nm), although on 146040 is not found to be active against the t315i mutant. represents first dual pi3k and bcr-abl inhibitor that targets stat3 stat5 pathways. disrupts oncogenic activity of both by targeting upstream activators, including α δ isoforms as well wild type mutant bcr-abl. highly potent in killing hematologic tumor cells with ic₅₀ values in the 150 to 1,000 nM range. Following treatment with ON 146040, STAT3 and STAT5 phosphorylation are down-regulated in leukemia and myeloma cells^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

489.55

C₂₄H₂₃N₇O₃S

1404231-34-0

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Targeting oncogenic STAT3 and STAT5 signaling with on 146040, a small molecule inhibitor of PI3K α/δ and BCR-ABL.